Australian Clinical Labs FY26 slides: margins expand despite revenue headwinds

Australian Clinical Labs (ACL) reported its FY26 financial results on August 17, 2026, demonstrating strong resilience in a challenging pathology market. The company's CEO, Melinda McGrath, was succeeded by Greg Horan, with Matthew Cordingley continuing as CFO. Despite a slight decline in revenue, ACL managed to expand profitability and enhance margins, which were particularly impressive given the market headwinds and operational pressures.

Total revenue for the year amounted to $735.8 million, representing a 0.7% decrease from the previous year. This decline was primarily driven by weak market conditions and the company's strategic decision to exit unprofitable contracts. However, the revenue decline did not dampen the company's ability to improve its underlying profitability.

Underlying EBIT reached $69.2 million, marking a 1.7% increase year-over-year. The EBIT margin expanded by 20 basis points to 9.4%, reflecting a significant achievement considering the revenue headwinds and labor cost pressures.

The company's net profit after tax increased by 4.3% to $35.5 million, while earnings per share rose 8.5% to 18.3 cents. Australian Clinical Labs maintained a robust return on invested capital of 25.2%, a figure that placed the company above the 75th percentile of the ASX 300. The management attributed these improvements to a combination of disciplined financial operations and strategic initiatives.

Key operational highlights included industry-leading labor costs of 43.5% of revenue and a 10.4% year-over-year increase in laboratory efficiency, measured by panels processed per full-time equivalent employee. The adoption of route optimization programs led to a reduction in courier travel by 950,000 kilometers. Revenue diversification efforts were also successful, with commercial contract revenues increasing by 17% and revenue from genetic and non-Medicare services growing by 7.4%.

As a result, nearly 20% of the company's total revenue now comes from non-Medicare sources, reducing its dependence on government fee schedules that have faced cuts.

The company's digitalization initiatives also gained momentum, with 39,000+ referrers connected to the platform and over 50% of referral forms automated. Additionally, an optical character recognition (OCR) project utilizing artificial intelligence was launched during the year and is expected to bring further back-office savings in FY27.

Despite a decline in total revenue, the composition of revenue improved significantly. The company exited unprofitable collection centers and sub-economic contracts, while growing higher-margin commercial and specialty testing revenues. Underlying EBITDA reached $204.5 million, representing a 27.8% margin, and underlying net profit attributable to shareholders (NPAT) was $24.0 million.

The company returned $47.1 million to shareholders through dividends and share buybacks, which accounted for 10.7% of the current market capitalization.